Skip to main content
Clinical Trials/NCT00086385
NCT00086385
Completed
Phase 3

Maintaining Nonsmoking: Older Smokers

University of California, San Francisco1 site in 1 country403 target enrollmentSeptember 2001

Overview

Phase
Phase 3
Intervention
Nicotine polacrilex, Bupropion
Conditions
Tobacco Use Disorder
Sponsor
University of California, San Francisco
Enrollment
403
Locations
1
Primary Endpoint
Participants Abstinent From Cigarettes
Status
Completed
Last Updated
11 years ago

Overview

Brief Summary

The purpose of this study was to examine pharmacological and psychological interventions for smokers over 50.

Detailed Description

The overall goals of this line of research were to prevent relapse to cigarette smoking, and to understand the processes related to smoking and relapse. The specific aims of the current study were to test a series of hypotheses about the efficacy and cost-effectiveness of long-term, tailored interventions in chronic, older smokers and the interaction of these interventions with gender and depression. Participants were 50 years or older and smoker 10 or more cigarettes per day. Baseline assessments includes measures of smoking behavior, nicotine dependence, depression diagnosis, demographics and life circumstances and measures of anger, depression and mood disturbance, stress, social support, health status, motivation for changed and drug and alcohol use.

Registry
clinicaltrials.gov
Start Date
September 2001
End Date
March 2009
Last Updated
11 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Arms & Interventions

Brief Treatment

Pharmacological Treatment - Subjects received 12 weeks of bupropion treatment and 10 weeks of nicotine replacement treatment (NRT) Brief Counseling - The counseling intervention consisted of five 90-minute group meetings. There was no further treatment during Weeks 12-52.

Intervention: Nicotine polacrilex, Bupropion

Extended NRT

Pharmacological Treatment - Following completion of the Brief Treatment, subjects assigned to this condition would continue receiving NRT for up to 52 weeks. Subjects in this condition would be encouraged to continue NRT through Week 24. If a subject terminated NRT and resumed smoking, before Week 50, would be instructed to set a quit date and resume NRT. Counseling Treatment - This is identical to the Brief Counseling described above.

Intervention: Nicotine polacrilex, Bupropion

Tailored/No Extended NRT

This condition was identical to the Tailored/NRT condition except that no NRT was available after completion of the Brief Treatment.

Intervention: Nicotine polacrilex, Bupropion

Extended Tailored Counseling + NRT

Tailored Counseling Treatment- The primary goal of the extended treatment was to prevent relapse. Secondary goal was to encourage initiation of abstinence for those who have not attained it by Week 12, and re-initiation of abstinence after slips. Subjects would participate in the Brief Treatment followed by individual sessions. The first extended treatment counseling session would occur at Week 10. Additional sessions would be held every two weeks then every four weeks, and finally at Weeks 44 and 52. Each session would be 20-30 minutes long. Between sessions subjects would be contacted by phone for brief check-ins (5-10 minutes).

Intervention: Nicotine polacrilex, Bupropion

Outcomes

Primary Outcomes

Participants Abstinent From Cigarettes

Time Frame: Two years

Primary outcome variable was 7-day point prevalence cigarette abstinence verified biochemically at week 104

Study Sites (1)

Loading locations...

Similar Trials